Russ Wada

Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2‐Positive Breast Cancer and Other Solid Tumors

Ophelia Yin, Yuan Xiong, Seiko Endo et al. · Clinical Pharmacology & Therapeutics · 2020 · 60 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Exposure‐Response Relationships in Patients With HER2‐Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan

Ophelia Yin, Hiroji Iwata, Chia‐Chi Lin et al. · Clinical Pharmacology & Therapeutics · 2021 · 55 citations · Full text

Medicine, Oncology, Pharmacology +17

Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer

Colby S. Shemesh, Pascal Chanu, Kris M. Jamsen et al. · Journal for ImmunoTherapy of Cancer · 2019 · 43 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15

Development of a Subcutaneous Fixed‐Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose‐Finding Study

Whitney P. Kirschbrown, Chris Wynne, Matts Kågedal et al. · The Journal of Clinical Pharmacology · 2018 · 37 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Mechanistic pharmacokinetic/pharmacodynamic modeling of in vivo tumor uptake, catabolism, and tumor response of trastuzumab maytansinoid conjugates

Russ Wada, Hans K. Erickson, Gail D. Lewis Phillips et al. · Cancer Chemotherapy and Pharmacology · 2014 · 29 citations

Pharmacy, Pharmacokinetics, Pharmacology +17